INFI - Infinity Pharmaceuticals EPS beats by $0.01 misses on revenue

Infinity Pharmaceuticals (NASDAQ:INFI): Q3 GAAP EPS of -$0.12 beats by $0.01. Revenue of $0.43M (-14.0% Y/Y) misses by $0.11M. Shares +1%. Press Release Financial Outlook: Infinity’s 2021 financial guidance remains as follows: Net Loss: Infinity expects net loss for 2021 to range from $40 million to $50 million. Cash and Investments: Infinity expects to end 2021 with a year-end-cash, cash equivalents and available for sale securities balance ranging from $70 million to $80 million. Infinity’s financial guidance does not include additional funding or business development activities.

For further details see:

Infinity Pharmaceuticals EPS beats by $0.01, misses on revenue